StockData

Cytokinetics vs Foghorn Therapeutics

CYTK and FHTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CYTK and FHTX compare

Foghorn Therapeutics is the larger company, worth 17 times as much as Cytokinetics ($109M against $6.4M).

Foghorn Therapeutics grew revenue faster over the last twelve months (52.0% versus −21.1% for Cytokinetics).

Foghorn Therapeutics keeps more of each dollar of sales as profit, with a net margin of −176% compared with −1321% at Cytokinetics.

Foghorn Therapeutics scores higher on the StockData Score (9 against 4 for Cytokinetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCYTKFHTX
Size and price
Market cap$6.4M$109M
Share price$51.65$1.83
Change, 1 year−22.3%−61.0%
Change, 5 years32.3%−86.6%
Beta (5Y)1.122.82
Employees673106
StockData Score
Total score49 (better)
Valuation score11
Growth score12 (better)
Performance score11
Health score15 (better)
Dividend score00
Valuation
P/S0.1× (better)3.0×
FCF yield−9034%−77.6% (better)
Growth
Revenue growth (TTM)−21.1%52.0% (better)
Revenue growth, 5Y average9.5%135% (better)
Profitability
Operating margin−1046%−198% (better)
Net margin−1321%−176% (better)
FCF margin−858%−229% (better)
Financial health
Current ratio6.66 (better)3.36
Altman Z-score−3.37 (better)−4.61
Piotroski F-score22
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions115%75.6%
Held by insiders0.68%36.3%
Insider net buying, 12 months−$51.5M–
Short interest, % of float13.0%6.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.